CMD Generated $40.5 Million in 2025 Revenue, Representing 32% Year-Over-Year Growth Compared with CMD’s Full-Year 2024 Pro Forma Revenue, Which Reflects the Full Year of CMD Operations for Comparability CMD’s 2025 Adjusted EBITDA Increased to $14.3 Million from $7.7 Million in the Prior Year on a Pro Forma Basis, a 84% Year-Over-Year Increase CMD Management Noted a Record Bid Pipeline Exceeding $160 Million Kyle’s Generated $6.6 Million in 2025 Revenue, Up 24% from $5.3 Million in 2024. Adjusted EBITDA Mor ...

Group 1 - electroCore, Inc. announced the appointment of Seth Abrams as VP of Sales effective April 1, 2026, and Michael Fox as Chief Operating Officer effective April 13, 2026 [1] - The Compensation Committee granted 30,000 restricted stock units (RSUs) to Mr. Abrams and 70,000 RSUs to Mr. Fox as part of their employment inducement [1] - The RSUs will vest in three equal parts on the first, second, and third anniversaries of the grant date, contingent on continued employment [1] Group 2 - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore for chronic pain treatment and Quell® for fibromyalgia, utilizing non-invasive neuromodulation technology [2] - electroCore also markets handheld products like Trvuaga and TAC-STIM for general wellness and human performance enhancement [2]

Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [2] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [2] Market Position and Strategy - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access through various collaboration opportunities [3] - The company is advancing its expertise in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [3] Upcoming Events - Esperion will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET, with a live webcast available on its website [1]

Core Viewpoint - Gentex Corporation will release its First Quarter 2026 financial results on April 24, 2026, before the market opens, and will host a conference call to discuss these results [1]. Group 1 - The conference call for the investment community is scheduled for 9:30 AM ET on the same day [1]. - A live audio webcast of the call will be available to the general public [2]. - Participants can register for the call to receive dial-in numbers and a unique PIN, with a recommendation to join 10 minutes prior to the event [2]. Group 2 - A replay of the webcast will be available approximately 24 hours after the call concludes [3]. - Contact information for Gentex Investor Relations is provided for further inquiries [3].

Core Insights - Catheter Precision, Inc. achieved significant growth in 2025, with a revenue increase of 95% year-over-year, reaching $819 thousand compared to $420 thousand in 2024 [14] - The company expanded its operations by acquiring Flyte, a regional air mobility company, which diversifies its business into aviation alongside its medical device platform [5][6] Financial Performance - For the full year 2025, the company reported a gross margin of 92.3%, up from 90.0% in 2024 [14] - The net loss for 2025 was $17.2 million, with $7.8 million being non-cash, compared to a net loss of $16.6 million in 2024, of which $7.5 million was non-cash [14] - In Q4 2025, revenue was $238 thousand, a 60% increase from $148 thousand in Q4 2024, with a gross margin of 91.6% [14] Operational Highlights - The company made strides in clinical and commercial validation, expanding its customer base and advancing commercialization efforts in Europe [2][3] - The VIVO and LockeT platforms demonstrated clinical value, with 32 new customers added and the first commercial sales of LockeT in Europe [7][8] Strategic Outlook - The acquisition of Flyte positions the company to tap into a rapidly growing market, enhancing its diversified platform across healthcare technology and regional aviation [5][6] - Management believes that the initiatives undertaken create a framework for accelerated growth and potential re-rating as execution milestones are achieved [9]

Core Insights - ZenaTech's subsidiary, ZenaDrone, has developed the IQ Aqua, an autonomous underwater vehicle (AUV) prototype aimed at defense and commercial markets, particularly for undersea mine detection [1][2] - The IQ Aqua expands ZenaDrone's product line into underwater robotics, complementing existing air, land, and water surface drone operations [1] - The prototype has shown successful autonomous navigation and mobility in controlled environments, with plans for outdoor field testing in the U.S. and internationally [1] Defense Applications - The IQ Aqua is designed to address the critical need for autonomous mine detection, which poses a significant threat in maritime defense [2] - Future defense applications include mine detection, covert underwater intelligence, surveillance, reconnaissance (ISR), and port threat detection [2] - The current prototype operates in a tethered configuration, with plans for a next-generation model that will be tether-free and GPS-independent [2] Commercial Use - The design of the IQ Aqua is suitable for autonomous inspections of offshore energy pipelines, subsea cables, and maritime infrastructure, reducing the need for costly diver and manned vessel operations [3] - The Gulf Cooperation Council nations, including the UAE, Saudi Arabia, and Qatar, are identified as priority markets due to their extensive offshore hydrocarbon assets and port security needs [3] Market Potential - The global underwater drone market is projected to exceed $16 billion by 2034, with the defense and security segment being the fastest-growing application category [4] - ZenaTech is targeting U.S. defense customers, NATO partners, and Gulf Cooperation Council nations as the IQ Aqua program progresses [4] - The company plans to provide updates on development milestones as they are achieved [4]

Core Insights - Rocket Doctor AI Inc. has appointed Dr. Anikia Nelson as Director of Product and Bilal Malik as Director of Engineering to enhance its digital health platform and support growth in North America [1][8] Group 1: Leadership Appointments - Dr. Anikia Nelson brings over a decade of experience in clinical care and product strategy, previously serving as Physician Strategy Manager at Doximity and Senior Director at Clarify Health Solutions [2][3] - Bilal Malik has more than ten years of experience in engineering, focusing on AI-enabled, cloud-native platforms, and previously led AI strategy at Pricedex Software [4][5] Group 2: Strategic Goals - The appointments aim to strengthen product direction, platform innovation, and scalability, enhancing Rocket Doctor's ability to deliver high-quality healthcare solutions [1][7] - The company is focused on expanding its reach in underserved markets and enhancing its AI capabilities to improve healthcare accessibility [7][13] Group 3: Company Overview - Rocket Doctor AI Inc. provides AI-powered solutions designed to enhance the patient journey and has supported over 300 MDs in managing more than 700,000 patient visits [11][12] - The company aims to reduce administrative burdens and improve physician-patient interactions, particularly in rural and underserved communities [13]

Vaisala XweatherPress Release March 31, 2026 Vaisala Xweather 2026 EV Range Report Reveals the States, Highways, and Hidden Weather Factors Shaping Your Charge Vaisala Xweather today released its 2026 EV Range Report, a data-driven look at how weather and road conditions shaped electric vehicle (EV) range across the contiguous United States and Europe between March 2025 and February 2026. The analysis reveals the best and worst locations for EV range, the highway corridors where drivers gain or lose the mos ...

Core Viewpoint - Tokyo Lifestyle Co., Ltd. has entered into a master agreement with TASLY (HONG KONG) INTERNATIONAL HOLDING COMPANY LIMITED for the distribution of health products, cosmetics, and liquors, aiming to strengthen its presence in China's health product market [1][4]. Group 1: Agreement Details - The agreement allows Tokyo Lifestyle to sell its premium health products, cosmetics, and liquors to TASLY HONG KONG on an outright basis for one year starting March 1, 2026, with specific terms to be agreed upon in individual agreements [2]. - Updates on the transaction's progress will be provided by Tokyo Lifestyle periodically [2]. Group 2: Company Background - TASLY HONG KONG is a subsidiary of Tasly Holding Group Co., Ltd., a prominent player in China's pharmaceutical and healthcare services sector, recognized as one of the top 500 manufacturing enterprises in the country [3]. - The nutraceuticals market in China was valued at US$58.04 billion in 2024 and is projected to reach US$109.89 billion by 2033, with a compound annual growth rate (CAGR) of 7.38% [3]. Group 3: Strategic Implications - The collaboration is expected to create strong synergies and a multiplier effect by combining Tokyo Lifestyle's diverse product portfolio with TASLY HONG KONG's extensive distribution network [4]. - This partnership is anticipated to enhance brand recognition and distribution capabilities across East Asia, potentially unlocking further partnership opportunities with leading brands in China [5].

Core Insights - YD Bio Limited has launched the EG Telehealth Platform in collaboration with EG BioMed, marking a significant step in the commercialization of early cancer detection and decentralized clinical services across the U.S. [1][9] Group 1: Platform Launch and Capabilities - The EG Telehealth Platform is now operational and accessible in 44 U.S. states, Washington D.C., and Guam, supported by a nationwide network of licensed physicians [2][6] - The platform is designed to support both diagnostic service delivery and future clinical program expansion, establishing a scalable digital infrastructure [2][5] - It enables detection and monitoring of multiple cancer types, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers, addressing significant unmet clinical needs [5] Group 2: Strategic Collaboration - The collaboration integrates YD Bio's digital health platform with EG BioMed's CLIA/CAP-certified laboratory capabilities, creating an ecosystem that connects patient access, physician oversight, and advanced cancer testing [3][4] - The platform introduces a decentralized, technology-driven approach that reduces barriers to patient access and allows for rapid scaling of diagnostic services without the need for physical infrastructure expansion [4][8] Group 3: Business Model and Future Plans - The operating model is scalable and asset-light, enabling service expansion without proportional increases in physical infrastructure or marketing expenditures [8] - The launch is part of YD Bio's broader strategy to build an integrated healthcare platform that bridges diagnostics, telehealth, and clinical development, with expectations for future partnerships and expanded diagnostic offerings [9][10] - YD Bio is advancing a merger with EG BioMed, anticipated to close in 2026, which is expected to enhance the company's capabilities in early cancer detection and diagnostic solutions [10][11]